Our product portfolio for SARS-CoV-2 provides you with the appropriate tools to answer all your diagnostic questions. It comprises three PCR tests for acute diagnostics, serological tests for differentiated detection of antibodies (IgA, IgM, IgG) against different SARS-CoV-2 antigens, a surrogate virus neutralisation test and an interferon-gamma release assay. The detection of specific anti-SARS-CoV-2 IgG using ELISA can be performed using not only venous blood samples, but also dried capillary blood (dried blood spots – DBS).
All tests are CE-marked. Moreover, the Anti-SARS-CoV-2 ELISA (IgG) and the EURORealTime SARS-CoV-2 have been approved for use in authorised laboratories by the U.S. Food and Drug Administration (FDA) via an Emergency Use Authorization (EUA)
Please consider the current US-specific instruction for use of the respective test system for validity of the FDA EUA.
NEW! The new EUROArray PneuVir enables the detection of 17 respiratory viruses – including SARS-CoV-2 – in one reaction and can thus help to avoid unnecessary antibiotic treatment in respiratory diseases.
Particularly fast: The new EURORealTime SARS-CoV-2 Fast enables highly specific and sensitive direct detection of SARS-CoV-2 by means of reverse-transcriptase real-time PCR within about 45 minutes.
NEW! Two test systems complement the product portfolio for COVID-19 serology: The Anti-SARS-CoV-2 RBD ChLIA (IgG) and the Anti-SARS-CoV-2 Omicron ELISA (IgG) enable quantification of anti-SARS-CoV-2 IgG antibodies. Press release
Update on the Omicron virus variant and the Quan-T-Cell: We do not yet have the experimental data to make statements on the possible effects of the Omicron variant on our Quan-T-Cell for the detection of SARS-CoV-2-specific T-cell activity. However, a variety of publications already confirm that T-cell reactivity against virus variants including Omicron is very stable and that it offers a certain level of variant-independent immune protection.
Read more here:
Detection of antibody response after vaccination: All COVID-19 vaccines currently used and approved in the EU are based on the wild type version of the spike protein (Wuhan-Hu-1). This means that antibodies formed after such vaccination can definitely be detected by the S1-based antibody assays from EUROIMMUN.
Using antibody tests based on the nucleocapsid protein (NCP), antibody reactions after vaccination can be distinguished after those formed after a contact with SARS-CoV-2 (does not apply for the use of vaccines which also contain an N component). A positive result in the Anti-SARS-CoV-2 NCP ELISA (IgG) indicates a past contact with the pathogen. However, even with a negative result a past SARS-CoV-2 infection cannot be excluded.
With our cooperation partner Homed-IQ, EUROIMMUN offers companies and individuals a simple and well-organised option for vaccination titer determination. You would like to learn more?
Read the whole article here.
Update on the Omicron virus variant and S1-based antibody detection: We do not yet have the experimental data to make statements on the possible effects of the Omicron variant on our serological test systems for the detection of antibodies against the S1 domain.
The acquisition of the serum samples required from patients positive for the Omicron variant but immunologically naive to other SARS-CoV-2 variants (i.e. who have never been in contact with the wild type form or other variants and were not vaccinated against SARS-CoV-2) proves very challenging.
Although it cannot generally be excluded that an infection with the SARS-CoV-2 variant Omicron leads to formation of antibodies which are not or only poorly detectable by the S1 wild type isolate (Wuhan-Hu-1) used by us, our in silico analyses do show that the amino acid sequence of the S1 domain and the RBD within the S1 domain of the Omicron variant and the wild type are highly homologous. Therefore, we do not expect a negative effect of the Omicron mutations on the performance of our test systems for antibodies against the S1 domain at this stage.
More information in our FAQ
Information on Omicron variant: According to in silico analysis, the new SARS-CoV-2 variant, called Omicron, is expected to be reliably detected by our EURORealTime SARS-CoV-2 and EURORealTime SARS-CoV-2/Influenza A/B tests systems. This also applies to the virus variants Alpha, Beta, Gamma, Delta, Lambda and Mu.
At this early stage it is not yet possible to make a statement about the possible effects of the Omicron variant on the performance of the EUROIMMUN antibody test systems or the interferon-gamma release assay Quan-T-Cell SARS-CoV-2.
EUROIMMUN carefully follows all reports and official information on the new SARS-CoV-2 variant from sources like the ECDC, WHO or FDA and immediately investigates possible effects on the test systems as soon as corresponding data is available.
More information in our FAQ
Efficient combination: one test for COVID-19 and flu - By using the EURORealTime SARS-CoV-2/Influenza A/B it is possible to keep an eye not only on the spread of COVID-19 but also of the upcoming flu in an efficient and resource-saving way.
NOW! with CE mark! The interferon-gamma release assay from EUROIMMUN is already established in research and allows determination of the activity of SARS-CoV-2-reactive T cells to support the evaluation of the cellular immune response after infection or vaccination.
Direct detection of the virus via RNA (RT-PCR) allow reliable identification of acute SARS-CoV-2 infections. With the EURORealTime SARS-CoV-2, the EURORealTime SARS-CoV-2 Fast and the EURORealTime SARS-CoV-2/Influenza A/B, EUROIMMUN offers two single-parameter tests for detection of the virus as well as a combination test for parallel detection of SARS-CoV-2 and influenza virus types A and B as well as for differentiation between these viruses.
The portfolio contains several ELISAs, a chemiluminescence immunoassay (ChLIA) and one immunoblot for the detection of antibodies against modified nucleocapsid protein (IgM and IgG) and against the domains S1 and S2 of the spike protein (IgA and IgG). The S1-based test systems Anti-SARS-CoV-2 QuantiVac ELISA (IgG) and Anti-SARS-CoV-2 RBD ChLIA (IgG) allow for quantification of the antibody concentration with the possibility of conversion into standardised units (BAU/ml). In addition, EUROIMMUN offers the Anti-SARS-CoV-2 Omicron ELISA (IgG), which uses the S1 domain of the SARS-CoV-2 Omicron variant. The serological product range is supplemented by the SARS-CoV-2 NeutraLISA, a surrogate virus neutralisation test for the detection of neutralising anti-S1/RBD antibodies, and the interferon-gamma release assay Quan-T-Cell for determination of the activity of SARS-CoV-2-reactive T cells. Both test systems are useful tools for evaluation of the immune response after infection with SARS-CoV-2 or vaccination with vaccines based on the spike protein. With the IgG ELISAs, dried capillary blood (dried blood spots, DBS) can be used as sample material, besides venous blood.
The ELISAs are used worldwide by renowned diagnostic laboratories, reference institutes, clinics and research institutions in order to diagnose and investigate COVID-19.
The EUROIMMUN Blood collection card can be used for sample collection and mailing of dried capillary blood samples (dried blood spots – DBS). It is suitable either for personal use in a home environment or for blood collection performed by a healthcare professional. The subsequent investigation of the samples for specific IgG antibodies against SARS-CoV-2 is performed in a laboratory.
Download flyers and further information material here.
EUROIMMUN develops and produces test systems for doctors and laboratories that cannot be performed by private individuals.